Many of the life sciences trends that are driving innovation today were here pre-COVID, but the pandemic was an accelerant. For all that it took, it gave life science researchers and developers new momentum, and from that momentum, hope.
As industry momentum continues, oligonucleotide manufacturers are making the leap from benchtop production to commercial scale. The challenges of large-scale oligo manufacturing, however, are exponential in comparison to small scale, lab-based operations.
During a global pandemic, the pharmaceutical industry must juggle the need for speed and the need to protect patient safety. A strong regulatory strategy makes it possible to accelerate drug development without getting slowed down by compliance considerations.
Oral solid dosage (OSD) products can take several different shapes, and with those different forms comes different production techniques and facility designs. Here’s what is involved with manufacturing an orally-ingested drug product.